RELA (Ab-435) Antibody

What is RELA (Ab-435) Antibody and what epitope does it recognize?

RELA (Ab-435) Antibody is a polyclonal antibody developed against a specific peptide sequence around amino acids 433-437 (E-G-T-L-S) derived from Human NFκB-p65. This antibody detects endogenous levels of total NFκB-p65 protein, making it suitable for studying the RELA subunit of the NF-κB transcription factor complex . The antibody recognizes this specific epitope across multiple species including human, mouse, rat, and monkey samples, providing versatility for cross-species research applications . When considering experimental designs, this epitope specificity is crucial for ensuring proper target detection and minimizing non-specific binding that could compromise research findings.

How does RELA (Ab-435) Antibody differ from phospho-specific RELA antibodies?

While RELA (Ab-435) Antibody detects total NFκB-p65 protein regardless of its phosphorylation status, phospho-specific antibodies such as Anti-Phospho-N kappa-p65 (T435) recognize only the phosphorylated form at specific residues (e.g., Thr435) . This fundamental difference determines their applications in research contexts. The RELA (Ab-435) Antibody is ideal for quantifying total p65 expression levels, while phospho-specific antibodies enable researchers to monitor specific activation states of the transcription factor . Methodologically, using both antibody types in parallel experiments allows for calculating the ratio of phosphorylated to total protein, providing insights into the degree of pathway activation under various experimental conditions.

What validated applications are recommended for RELA (Ab-435) Antibody?

The RELA (Ab-435) Antibody has been validated for multiple research applications with specific dilution recommendations:

The antibody has demonstrated specific binding to NFκB-p65 in various experimental contexts, including detection in COS7 cell extracts and human breast carcinoma tissue . When designing experiments, researchers should conduct preliminary titration experiments to determine optimal antibody concentrations for their specific sample types and detection methods.

How should researchers design controlled experiments using RELA (Ab-435) Antibody?

When designing experiments with RELA (Ab-435) Antibody, researchers should implement a randomized complete block (RCB) design to account for potential batch effects and experimental variability . This approach is particularly important when evaluating NFκB-p65 expression across multiple conditions or treatments. Methodologically, researchers should:

• Include appropriate positive controls (e.g., cell lines known to express high levels of RELA)

• Incorporate negative controls (e.g., samples where the primary antibody is omitted)

• Consider blocking peptide controls to confirm specificity, as demonstrated in the validation studies where the same antibody preincubated with blocking peptide showed minimal background signal

• Implement technical replicates (minimum of three) for each biological sample

• Randomize sample processing order to minimize systematic bias

This design strategy minimizes the impact of confounding variables and strengthens the reliability of experimental findings, following established principles of scientific rigor in immunological research .

What are the critical quality control metrics for validating RELA (Ab-435) Antibody in new experimental systems?

When implementing RELA (Ab-435) Antibody in a new experimental system, researchers must establish several quality control parameters:

These metrics align with established data quality criteria for research applications, emphasizing timeliness, completeness, accuracy, and comparability of results . Implementing these validation steps ensures that findings with the antibody are robust and reproducible across different experimental contexts.

How can RELA (Ab-435) Antibody be utilized to investigate NF-κB pathway activation in inflammatory disease models?

For advanced inflammatory disease research, RELA (Ab-435) Antibody can be employed in multi-parameter analyses to characterize NF-κB pathway dynamics. Methodologically, researchers should:

• Design time-course experiments capturing both early (30-60 minutes) and late (4-24 hours) NFκB-p65 activation phases

• Combine with phospho-specific antibodies (such as Anti-Phospho-N kappa-p65) to determine activation kinetics

• Implement dual immunofluorescence techniques to co-localize RELA with other pathway components

• Correlate nuclear translocation of RELA with downstream gene expression using chromatin immunoprecipitation (ChIP) assays

• Apply the antibody in tissue microarrays to evaluate RELA expression patterns across multiple patient samples

This comprehensive approach provides mechanistic insights into how inflammatory stimuli modulate NF-κB signaling in disease contexts. The validation studies showing RELA detection in breast carcinoma tissue demonstrate its effectiveness in clinical sample analysis .

What strategies should be employed when analyzing contradictory results between RELA protein expression and functional activity?

When researchers encounter discrepancies between RELA protein levels (detected with RELA (Ab-435) Antibody) and functional NF-κB activity, a systematic analytical approach is necessary:

• Evaluate post-translational modifications using phospho-specific antibodies (e.g., Anti-Phospho-N kappa-p65 (T435))

• Assess nuclear-cytoplasmic fractionation efficiency through subcellular localization studies

• Examine protein-protein interactions that might sequester or enhance RELA activity

• Investigate potential inhibitory mechanisms (e.g., IκB protein levels)

• Analyze proteasomal degradation rates of the RELA protein

This methodological framework parallels approaches used in transplantation research where contradictory antibody results required sophisticated analysis to resolve clinical correlations . Researchers should implement statistical methods that account for both biological and technical variability, such as mixed-effects models, to properly interpret apparently contradictory findings.

What quantitative methods are recommended for analyzing RELA (Ab-435) Antibody immunohistochemistry data?

For rigorous quantification of IHC data using RELA (Ab-435) Antibody, researchers should implement a structured analytical workflow:

This approach aligns with validation practices demonstrated in antibody testing where paraffin-embedded human breast carcinoma tissue showed differential staining patterns with specific blocking . For longitudinal studies, researchers should implement repeated measures statistical designs to account for within-subject correlations, similar to the statistical considerations outlined for randomized block designs .

How should researchers address potential artifacts and false positives when using RELA (Ab-435) Antibody in complex tissue samples?

When working with complex tissues, several methodological steps are essential to distinguish true RELA signals from artifacts:

• Implement proper antigen retrieval optimization through temperature and pH titration experiments

• Conduct parallel staining with alternative RELA antibodies recognizing different epitopes

• Apply Tyramide Signal Amplification (TSA) for low-abundance targets while monitoring background

• Utilize phosphatase treatment controls to differentiate phosphorylation-dependent signals

• Employ tissue-specific negative controls lacking RELA expression

• Validate key findings with orthogonal techniques (e.g., in situ hybridization for RELA mRNA)

These measures address the quality concerns highlighted in real-world data research where data accuracy and validation are paramount . The approach parallels validation methods demonstrated in the product literature where blocking peptides were used to confirm specificity .

What are the most common technical issues encountered with RELA (Ab-435) Antibody and their solutions?

Researchers frequently encounter specific technical challenges when working with RELA (Ab-435) Antibody:

These troubleshooting approaches are based on established practices for antibody-based detection methods. The storage recommendations from the product literature specifically note the importance of avoiding repeated freeze-thaw cycles to maintain antibody performance .

How can researchers optimize RELA (Ab-435) Antibody protocols for low-abundance targets in primary tissues?

For detecting low-abundance RELA in primary tissues, researchers should implement a systematic optimization strategy:

• Apply signal amplification methods such as biotin-streptavidin systems or tyramide signal amplification

• Extend primary antibody incubation to overnight at 4°C to enhance binding kinetics

• Optimize antigen retrieval methods specifically for the tissue type (e.g., citrate vs. EDTA buffers)

• Implement automated staining platforms to ensure consistent reagent application

• Consider proximity ligation assays (PLA) for detecting protein-protein interactions involving RELA with enhanced sensitivity

This approach incorporates principles from experimental design in biological research, where optimization of detection methods is crucial for reliable data generation . The specific dilution recommendations (1:50-1:200 for IHC) provided in the product literature should serve as starting points for further optimization based on specific sample characteristics .

How can RELA (Ab-435) Antibody be incorporated into multi-omics research frameworks?

For integrating RELA (Ab-435) Antibody into comprehensive multi-omics studies, researchers should:

• Combine antibody-based protein detection with transcriptomic analysis of NF-κB target genes

• Correlate RELA protein levels with chromatin accessibility in regulatory regions using ATAC-seq

• Implement mass spectrometry-based approaches to identify RELA protein interactors

• Design parallel single-cell analyses to assess heterogeneity in RELA expression across cell populations

• Develop computational models integrating RELA protein dynamics with downstream pathway activities

What considerations are important when using RELA (Ab-435) Antibody in multiplexed imaging approaches?

When implementing RELA (Ab-435) Antibody in multiplexed imaging protocols, several methodological considerations become critical:

These approaches align with advanced research applications where complex relationships between multiple proteins need to be assessed simultaneously. The polyclonal nature of RELA (Ab-435) Antibody should be considered when designing multiplexed panels, as it may exhibit broader epitope recognition than monoclonal antibodies .

What emerging research areas might benefit from RELA (Ab-435) Antibody applications?

The RELA (Ab-435) Antibody has significant potential in several emerging research fields:

• Single-cell protein analysis of NF-κB signaling heterogeneity in complex tissues

• Spatial transcriptomics correlated with RELA protein localization

• Drug discovery platforms targeting non-canonical roles of RELA in cellular processes

• Biomarker development for inflammatory diseases and cancer progression

• Investigation of RELA in non-classical cell types beyond the immune system

These research directions build upon the established applications of the antibody while extending into new methodological frameworks. The demonstrated cross-species reactivity of the antibody enables comparative studies across model organisms, enhancing translational relevance .

How might technological advances improve the application of antibodies like RELA (Ab-435) in future research?

Emerging technologies promise to enhance the utility of RELA (Ab-435) Antibody in research:

• Microfluidic antibody-based detection systems for real-time monitoring of NF-κB dynamics

• CRISPR-based tagging systems that can validate antibody specificity through genetic approaches

• Advanced computational algorithms for automated quantification of subcellular RELA distribution

• Nanobody development based on epitope mapping of successful antibodies like RELA (Ab-435)

• In situ sequencing technologies combined with protein detection for spatial multi-omics

These technological advances will address current limitations in antibody-based research, particularly regarding specificity validation and quantitative analysis. As emphasized in quality criteria for research data, continuous methodological improvements are essential for advancing scientific knowledge .